Log in

NYSEAMERICAN:VNRX - VolitionRX Stock Price, Forecast & News

$3.44
+0.11 (+3.30 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$3.02
Now: $3.44
$3.48
50-Day Range N/A
52-Week Range
$2.65
Now: $3.44
$6.84
Volume314,321 shs
Average Volume106,832 shs
Market Capitalization$141.75 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:VNRX
Previous SymbolNYSEMKT:VNRX
CUSIPN/A
CIKN/A
Phone646 650 1351

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees44
Market Cap$141.75 million
Next Earnings Date5/13/2020 (Estimated)
OptionableNot Optionable

Receive VNRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.


VolitionRX (NYSEAMERICAN:VNRX) Frequently Asked Questions

What is VolitionRX's stock symbol?

VolitionRX trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

How were VolitionRX's earnings last quarter?

VolitionRX Ltd (NYSEAMERICAN:VNRX) announced its quarterly earnings data on Tuesday, November, 12th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. The medical research company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.06 million. View VolitionRX's Earnings History.

When is VolitionRX's next earnings date?

VolitionRX is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for VolitionRX.

What price target have analysts set for VNRX?

2 Wall Street analysts have issued 12 month price objectives for VolitionRX's stock. Their forecasts range from $5.00 to $8.00. On average, they expect VolitionRX's stock price to reach $6.50 in the next year. This suggests a possible upside of 89.0% from the stock's current price. View Analyst Price Targets for VolitionRX.

What is the consensus analysts' recommendation for VolitionRX?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRX in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VolitionRX.

Has VolitionRX been receiving favorable news coverage?

News stories about VNRX stock have trended very negative this week, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. VolitionRX earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for VolitionRX.

Who are some of VolitionRX's key competitors?

What other stocks do shareholders of VolitionRX own?

Who are VolitionRX's key executives?

VolitionRX's management team includes the folowing people:
  • Dr. Martin Charles Faulkes, Exec. Chairman (Age 75)
  • Mr. Cameron Reynolds, Founder, CEO, Pres & Director (Age 48)
  • Dr. Jacob Vincent Micallef Ph.D., MBA, Chief Scientific Officer (Age 63)
  • Dr. Jason Bradley Terrell, Chief Medical Officer (Age 39)
  • Mr. Rodney Gerard Rootsaert LLB, Corp. Sec. (Age 48)

Who are VolitionRX's major shareholders?

VolitionRX's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.50%), Renaissance Technologies LLC (0.13%), California Public Employees Retirement System (0.05%), Advisor Group Inc. (0.05%), Oxford Asset Management LLP (0.03%) and State Street Corp (0.03%). Company insiders that own VolitionRX stock include Cameron John Reynolds, Corp Ltd Eight, Guy Archibald Innes and Martin Charles Faulkes. View Institutional Ownership Trends for VolitionRX.

Which major investors are selling VolitionRX stock?

VNRX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Geode Capital Management LLC. View Insider Buying and Selling for VolitionRX.

Which major investors are buying VolitionRX stock?

VNRX stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Oxford Asset Management LLP, State Street Corp and Advisor Group Inc.. Company insiders that have bought VolitionRX stock in the last two years include Cameron John Reynolds, Corp Ltd Eight, Guy Archibald Innes and Martin Charles Faulkes. View Insider Buying and Selling for VolitionRX.

How do I buy shares of VolitionRX?

Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is VolitionRX's stock price today?

One share of VNRX stock can currently be purchased for approximately $3.44.

How big of a company is VolitionRX?

VolitionRX has a market capitalization of $141.75 million. VolitionRX employs 44 workers across the globe.View Additional Information About VolitionRX.

What is VolitionRX's official website?

The official website for VolitionRX is http://www.volitionrx.com/.

How can I contact VolitionRX?

The medical research company can be reached via phone at 646 650 1351.


MarketBeat Community Rating for VolitionRX (NYSEAMERICAN VNRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  338
MarketBeat's community ratings are surveys of what our community members think about VolitionRX and other stocks. Vote "Outperform" if you believe VNRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/29/2020 by MarketBeat.com Staff

Featured Article: Diversification

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel